Johns Hopkins ABX Guide
Cefiderocol
INDICATIONS
FDA
FDA
- Patients ≥18 y/o for the treatment of the following infections caused by susceptible Gram-negative microorganisms:
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- MDR GNR (e.g., Pseudomonas, Acinetobacter, CRO) infections when no other alternatives are available
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: December 19, 2025
Citation
, Kathryn Dzintars, Pharm.D., BCPS, and Edina Avdic. "Cefiderocol." Johns Hopkins ABX Guide, The Johns Hopkins University, 2025. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540740/7/Cefiderocol.
K, Avdic E. Cefiderocol. Johns Hopkins ABX Guide. The Johns Hopkins University; 2025. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540740/7/Cefiderocol. Accessed December 26, 2025.
, K., & Avdic, E. (2025). Cefiderocol. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540740/7/Cefiderocol
K, Avdic E. Cefiderocol [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2025. [cited 2025 December 26]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540740/7/Cefiderocol.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Cefiderocol
ID - 540740
A1 - ,Kathryn Dzintars, Pharm.D., BCPS,
AU - Avdic,Edina,Pharm.D.
Y1 - 2025/12/19/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540740/7/Cefiderocol
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
